Apellis logo.jpg
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
April 21, 2021 07:00 ET | Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis logo.jpg
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 16, 2021 12:44 ET | Apellis Pharmaceuticals, Inc.
10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration Presentations support the potential of intravitreal pegcetacoplan, an investigational...
Apellis logo.jpg
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
April 13, 2021 07:00 ET | Apellis Pharmaceuticals, Inc.
Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007)Top-line data from Phase 3 DERBY...
Apellis logo.jpg
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
March 17, 2021 17:48 ET | Apellis Pharmaceuticals, Inc.; Sobi
Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels...
Apellis logo.jpg
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
March 10, 2021 09:15 ET | Apellis Pharmaceuticals, Inc.
Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass.,...
Apellis logo.jpg
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2021 16:05 ET | Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis logo.jpg
Apellis Provides Update on APL-9 for Severe COVID-19
March 04, 2021 16:05 ET | Apellis Pharmaceuticals, Inc.
Company will not pursue additional development of APL-9 for the treatment of severe COVID-19Interim review by independent data monitoring committee (DMC) found no meaningful reduction in the overall...
Apellis logo.jpg
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 16:01 ET | Apellis Pharmaceuticals, Inc.
Marketing applications for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency...
Apellis logo.jpg
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 22, 2021 08:00 ET | Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis logo.jpg
Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
February 18, 2021 16:05 ET | Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...